Latest Healthcare It News

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Global Health Limited trimmed its FY26 net loss by 12.5% to A$758,220, driven by a 5.5% lift in recurring SaaS revenue and a 20% cut in employee costs aided by AI integration, though going concern risks remain.

ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.

Stakk is on the cusp of completing its US$63 million acquisition of ParaScript, having secured shareholder approval and completed a A$27 million placement. The combined entity is poised to meet or exceed FY2027 revenue and EBITDA targets, reinforcing its digital trust platform strategy.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Ingenia Communities Group (ASX: INA) reported an 18% rise in FY26 EBIT to $193.4 million, beating guidance, while underlying EPS grew 16% to 35.8 cents. The group also extended its land lease development pipeline to 8,800 sites, underpinning future growth.

Embelton Limited has reported a solid 20.4% increase in revenue and a 34.7% jump in profit after tax for FY2026, underpinned by a strategic pivot away from residential construction towards infrastructure and social sectors. The company held its dividend steady amid improving cash flow and reduced borrowings.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

Oakridge International Limited has reversed its fortunes with a 42% revenue increase to $3.45 million and a return to profitability in FY2026, driven by healthcare technology sales and strategic platform enhancements.

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.